Funded Programs


the Mo is the catalyst for change
Research has beaten many diseases in recent history, and in time, we believe that research will beat prostate and testicular cancer. But we need to accelerate this reality and that’s why at Movember, we are changing the culture of science by breaking down barriers, by funding innovative research that builds powerful, collaborative, global teams.  It is through this pioneering new model that we will achieve our goal of improved clinical tests and treatments for men with prostate and testicular cancer.


At a national level Movember partners with the Prostate Cancer Foundation (PCF), who’s stated objective is to empower the world’s top scientific minds by cutting red tape and encouraging collaboration to speed breakthroughs. 
“Movember has initiated a growing international dialog on prostate cancer and men’s health and is an invaluable partner in energizing the global research enterprise for prostate cancer. Here in the US, unrestricted funding from Movember is helping the Prostate Cancer Foundation accelerate the world’s most promising research, enabling game-changing projects from whole genome sequencing and the development of innovative therapies. These will help men with advanced prostate cancer live longer, more productive lives than ever before.”
- Dr. Jonathan Simons, CEO and President of the Prostate Cancer Foundation
At a global level the Movember Foundation funds the Global Action Plan (GAP), an international research collaboration initiative that is accelerating outcomes by providing researchers from around the world the opportunity to work together on specific research projects. Take a look at the video below for a brief overview of GAP and details of the first funded project.

As a result of working with prostate and testicular cancer partners from around the world, Movember identified an opportunity to accelerate research outcomes by providing researchers across the world the opportunity to work together on specific projects.
By bringing together international researchers, GAP facilitates a new and unprecedented level of global research collaboration, not previously seen within the cancer community. Over time, researchers coming together to share details of what worked and what didn’t will avoid duplication of research efforts and deliver a greater return on the funds that Movember and other organisations invest in prostate and testicular cancer research.
Today there are five GAP projects underway, which have brought together more than 250 of the world's top prostate and testicular cancer researchers, all of them committed to working together on research and sharing their knowledge in the area.


A small percentage of the funds raised in each country are allocated to a global fund.  The global fund is then allocated to one priority project each year that is determined by an independent Global Scientific Committee (GSC). The GSC is comprised of internationally renowned prostate cancer experts from around the world, and chaired by Dr. Colleen Nelson. Each year, Movember’s Global Scientific Committee (GSC) comes together to determine a research focus that would best benefit from global collaboration. Once the priority area is endorsed by Movember’s Board, the best prostate or testicular cancer researchers in the world from both Movember and non-Movember countries are brought together and funded to collaborate and address a pre-determined issue or area of concern.
Once the researchers are recruited, they collaborate through a number of mediums, including regular conference calls, annual face-to-face meetings and participation on Movember’s online collaboration platform called Promoveo.
Promoveo is a Latin phrase which means to push forward, move ahead, advance and that is exactly the aim of the online platform which Movember has custom built for the prostate and testicular cancer research community. At a very simple level, it’s a bit like LinkedIn with discussion and collaboration forums, in short it:
  • Connects the global prostate and testicular cancer communities
  • Showcases the research program and its participants
  • Allows researchers to collaborate by sharing knowledge
  • Allows researchers to search for and share resources
  • Provides a project tracking and management tool
“Our vision is to have an everlasting impact on the state of men’s health and it’s to this end that we've established our GAP. We believe that getting the best researchers from around the world to work together on key challenges will accelerate breakthroughs that will ultimately benefit men with prostate cancer. Further, we believe that team-based research, performed across borders with a strong collaborative mindset, can deliver innovation and knowledge sharing that leads to an acceleration of results that benefit men diagnosed and living with prostate cancer today.”
- Head of Programs at Movember, Paul Villanti

Provided below is a series of videos that highlight some of the research being funded. 
If you’d like to view a complete list of all the research being funded by Movember please review the research report cards.

Prostate Cancer Foundation President and CEO, Dr. Jonathan Simons reviews the recent state of prostate cancer and how Movember is changing the landscape.
PCF Creativity Award grant winner Dr. Steve Cho at the Johns Hopkins University School of Medicine and his team have evaluated an imaging technique, PSMA-based PET, which noninvasively pinpoints the location of prostate cancer on a smaller scale and with greater accuracy. This imaging system has the potential to more easily determine the stage of prostate cancer prior to initial treatment and determine those who might benefit from more aggressive treatment versus active surveillance.
Due to Movember and PCF funds, scientists have been able to construct a complete genetic map of prostate cancer. This means patients will eventually be able to work with their doctors to map the individual genetic alterations of their prostate cancer to determine their specific treatment option.
Due to Movember and PCF funds, researchers identified 27 different types of prostate cancer. This discovery will ultimately answer the agonizing question facing men with prostate cancer: does their cancer need immediate treatment, will active surveillance be sufficient, and if more treatment is needed, which type of prostate cancer needs which unique combination of new medicines? Recently, new research has discovered an additional three types of prostate cancer.